Sceneay J, McAllister SS. The skinny on obesity and cancer. Nat Cell Biol. 2017;19(8):887-888. doi:10.1038/ncb3583
Herrera KNG, Zaganjor E, Ishikawa Y, et al. Small-Molecule Screen Identifies De Novo Nucleotide Synthesis as a Vulnerability of Cells Lacking SIRT3. Cell Rep. 2018;22(8):1945-1955. doi:10.1016/j.celrep.2018.01.076
Martins MM, Zhou AY, Corella A, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015;5(2):154-67. doi:10.1158/2159-8290.CD-14-0552
McPherson AW, Roth A, Ha G, et al. ReMixT: clone-specific genomic structure estimation in cancer. Genome Biol. 2017;18(1):140. doi:10.1186/s13059-017-1267-2
Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690-705.e9. doi:10.1016/j.ccell.2018.03.014
Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475(7355):231-4. doi:10.1038/nature10167
Giltnane JM, Hutchinson KE, Stricker TP, et al. Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9(402). doi:10.1126/scitranslmed.aai7993
Cho SW, Xu J, Sun R, et al. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cell. 2018;173(6):1398-1412.e22. doi:10.1016/j.cell.2018.03.068
Saji S, Kawakami M, Hayashi SI, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005;24(28):4531-9. doi:10.1038/sj.onc.1208646
Ben-David U, Siranosian B, Ha G, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560(7718):325-330. doi:10.1038/s41586-018-0409-3